ReviewFrontiers in cell and developmental biology2021
Non-coding RNA Activated by DNA Damage: Review of Its Roles in the Carcinogenesis.
Review in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- The Role of Liquid Biopsy in the Diagnosis of Oral Squamous Cell Carcinoma: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- LncRNAs-associated to genomic instability: A barrier to cancer therapy effectiveness.Frontiers in genetics · 2022Pooled it
- Review
- A multi-biomarker nomogram based on miR-155-5p and NETs predicting deep vein thrombosis risk stratification.Thrombosis journal · 2026Article
- Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer.European journal of medical research · 2025Article
- Role of Hypoxia-Associated Long Noncoding RNAs in Cancer Chemo-Therapy Resistance.International journal of molecular sciences · 2025Review
- Oncogenic role ofTranslational cancer research · 2024Article
- Review
- "Salivary LINC00657 and miRNA-106a as diagnostic biomarkers for oral squamous cell carcinoma, an observational diagnostic study".BMC oral health · 2023Article
- Expression ofMolecular therapy. Nucleic acids · 2023Article
- hASCs-derived exosomal miR-155-5p targeting TGFβR2 promotes autophagy and reduces pyroptosis to alleviate intervertebral disc degeneration.Journal of orthopaedic translation · 2023Article
- A review on the role of MCM3AP-AS1 in the carcinogenesis and tumor progression.Cancer cell international · 2022Review
- Suppression of lncRNA NORAD may affect cell migration and apoptosis in gastric cancer cells.Molecular biology reports · 2022Article
- A long non-coding RNA with important roles in the carcinogenesis.Frontiers in cell and developmental biology · 2022Review
- Biological Functions and Molecular Mechanisms of MiR-608 in Cancer.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long intergenic non-coding RNA 00657 (LINC00657) or "non-coding RNA activated by DNA damage" (NORAD) is an extremely conserved and copious long non-coding RNA (lncRNA). This transcript has pivotal role in the preservation of genome integrity. Several researches have appraised the role of NORAD in the evolution of human cancers with most of them indicating an oncogenic role for this lncRNA. Several miRNAs such as miR-199a-3p, miR-608, miR-155-5p, miR-590-3p, miR-495-3p, miR-608, miR-202-5p, miR-125a-3p, miR-144-3p, miR-202-5p, and miR-30a-5p have been recognized as targets of NORAD in different cancer cell lines. In addition, NORAD has interactions with cancer-related pathways, particularly STAT, TGF-β, Akt/mTOR, and PI3K/AKT pathway. Over-expression of NORAD has been related with poor clinical outcome of patients with diverse types of neoplasms. Collectively, NORAD is a prospective marker and target for combating cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.